Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Limertinib (ASK120067) Combined With Radiotherapy as First-Line Treatment in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases: A Single-Arm, Multicenter, Prospective Phase II Study

NCT07413952 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT07413952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07413952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Limertinib (ASK120067) Combined With Radiotherapy as First-Line Treatment in Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases: A Single-Arm, Multicenter, Prospective Phase II Study
Lead sponsor
The First Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
December 31, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc